Repligen Corporation is a bioprocessing company that specializes in developing and manufacturing products that support the process of biologics, specifically in the production of therapeutics such as monoclonal antibodies and gene therapies
The company offers a range of innovative solutions, including critical components, systems, and services that enhance efficiency and reliability in biomanufacturing. By focusing on advanced technologies and customizable solutions, Repligen aims to improve the workflow of biopharmaceutical production, making it more cost-effective and scalable for its clients in the life sciences industry.
Repligen Q3 earnings beat expectations with $0.43 EPS and $154.87 million in sales. The company raises 2024 EPS guidance and reports strong growth in CDMO and equipment.
Companies Reporting Before The Bell • Gatos Silver (NYSEGATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million.
Repligen reports Q2 sales of $154.1 million, closely matching the consensus estimate. Adjusted gross margin fell to 49.6% from 50.2%, with an EPS of $0.33. CEO Tony J. Hunt highlights strong Pharma demand and a pickup in CDMO activity.
Repligen posts Q4 2023 results. CEO Tony Hunt highlights order strength in Filtration and Analytics. Positive momentum in new modalities; 2024 revenue forecast: $620-$650 million.
A company with a $50 price per share might have a million shares outstanding or a billion shares outstanding. And unless you know, you don't know the price tag of the stock you're about to buy.
Shares of Intel Corporation (NASDAQINTC) fell sharply during Friday’s session. Intel reported upbeat results for its fourth quarter, but issued a weak forecast for the first quarter.
